Fulcrum Capital’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.02M Sell
4,031
-345
-8% -$80.4K 0.21% 50
2026
Q1
$1.07M Sell
4,376
-197
-4% -$45.9K 0.23% 48
2025
Q4
$946K Hold
4,573
0.19% 49
2025
Q3
$848K Hold
4,573
0.17% 49
2025
Q2
$699K Sell
4,573
-408
-8% -$62.7K 0.15% 54
2025
Q1
$826K Buy
4,981
+1,029
+26% +$161K 0.18% 51
2024
Q4
$572K Buy
3,952
+254
+7% +$39.4K 0.12% 57
2024
Q3
$599K Buy
3,698
+96
+3% +$15.3K 0.13% 58
2024
Q2
$526K Hold
3,602
0.12% 60
2024
Q1
$570K Buy
3,602
+129
+4% +$20.5K 0.14% 59
2023
Q4
$544K Buy
+3,473
New +$533K 0.14% 59
2023
Q3
Sell
-3,450
Closed -$571K 112
2023
Q2
$571K Sell
3,450
-59
-2% -$9.52K 0.15% 60
2023
Q1
$544K Sell
3,509
-100
-3% -$16.1K 0.15% 64
2022
Q4
$638K Buy
3,609
+800
+28% +$138K 0.18% 61
2022
Q3
$459K Buy
2,809
+30
+1% +$5.08K 0.14% 60
2022
Q2
$493K Sell
2,779
-7
-0.3% -$1.25K 0.16% 53
2022
Q1
$494K Sell
2,786
-160
-5% -$27.2K 0.13% 50
2021
Q4
$504K Sell
2,946
-564
-16% -$92.3K 0.11% 61
2021
Q3
$567K Sell
3,510
-280
-7% -$47.8K 0.14% 56
2021
Q2
$624K Sell
3,790
-36,042
-90% -$5.97M 0.16% 50
2021
Q1
$6.55M Sell
39,832
-550
-1% -$89K 1.88% 26
2020
Q4
$6.36M Buy
40,382
+3,002
+8% +$443K 1.9% 27
2020
Q3
$5.57M Sell
37,380
-2,911
-7% -$431K 2.01% 27
2020
Q2
$5.67M Sell
40,291
-3,556
-8% -$518K 2.15% 27
2020
Q1
$5.75M Sell
43,847
-1,211
-3% -$172K 2.61% 18
2019
Q4
$6.57M Buy
45,058
+1,591
+4% +$216K 2.04% 24
2019
Q3
$5.62M Buy
43,467
+1,514
+4% +$199K 1.92% 25
2019
Q2
$5.84M Sell
41,953
-6,167
-13% -$854K 2.14% 22
2019
Q1
$6.73M Buy
48,120
+2,185
+5% +$293K 2.54% 12
2018
Q4
$5.93M Sell
45,935
-3,436
-7% -$479K 2.67% 13
2018
Q3
$6.82M Buy
49,371
+1,726
+4% +$229K 2.66% 11
2018
Q2
$5.78M Sell
47,645
-216
-0.5% -$26.9K 2.76% 14
2018
Q1
$6.13M Buy
47,861
+1,249
+3% +$169K 2% 17
2017
Q4
$6.51M Buy
+46,612
New +$6.49M 2.11% 14

Other funds holding JNJ

Fulcrum Capital's JNJ Position: Q2 2026 in Review

Fulcrum Capital reduced its Johnson & Johnson (JNJ) stake by 7.9% in Q2 2026, selling an estimated $80.4K and leaving 4,031 shares worth $1.02M. The position accounts for 0.21% of the portfolio, ranked #50.

Fulcrum Capital first reported a position in JNJ in Q4 2017 and has held it in 34 quarters since. The position peaked at $6.82M in Q3 2018. 4,665 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Fulcrum Capital held 4,031 shares of Johnson & Johnson worth $1.02M as of Q2 2026.
  • Fulcrum Capital sold 345 Johnson & Johnson shares in Q2 2026, an estimated $80.4K.
  • Johnson & Johnson made up 0.21% of Fulcrum Capital's portfolio in Q2 2026, its #50 holding.
  • Fulcrum Capital first reported a position in Johnson & Johnson in Q4 2017 and has held it in 34 quarters since.
  • Fulcrum Capital's Johnson & Johnson position peaked at $6.82M in Q3 2018.
  • 4,665 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Fulcrum Capital's 13F filing for Q2 2026, filed 21 Jul 2026.